drugset / Trial / NCT05772156

Prophylactic Methylergonovine for Twin Cesarean

NCT05772156

Phase 4 Completed 66 enrolled Columbia University
RandomizedParallel-groupDouble-blindPrevention

Summary

Obstetrical hemorrhage (excessive bleeding related to pregnancy) is a leading cause of maternal morbidity (disease or symptom of disease) and mortality (death) worldwide with a significantly higher frequency and severity following cesarean delivery. Twin gestations (twin pregnancy) are at particularly higher risk for postpartum hemorrhage, yet the management of obstetrical bleeding following twin delivery remains identical to singleton delivery. The purpose of this study is to understand the effect of prophylactic methylergonovine on blood loss in scheduled twin pregnancy cesarean deliveries. Participants will be randomized (like tossing a coin) to Methylergonovine (investigational drug) or water with salt (saline) (placebo). Methylergonovine or saline will be given as an injection immediately after delivery.

Timeline

Start
2023-03-07
Primary completion
2024-03-03
Completion
2024-03-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylergonovine Small molecule 200 ug Intramuscular

Indications